Rigel Pharmaceuticals Inc. Common Stock (RIGL)

FairStock Score: 95/100 — HIGH CONVICTION

Key Financials

Strengths

• Generates $75 million in annual free cash flow (13.3% yield on market cap)
• High return on equity of 185.9% demonstrating efficient capital deployment
• Conservative balance sheet with debt-to-equity of just 0.14, providing financial flexibility
• Superior net profit margin of 91.1% indicating pricing power and operational efficiency
• Revenue growth of 21.2% demonstrates strong top-line momentum

Concerns

• Altman Z-Score of 0.6 places it in the financial distress zone—elevated bankruptcy risk

AI Analysis

Rigel Pharmaceuticals Inc. Common Stock is a micro-cap healthcare company valued at $563 million. The business generates $294 million in annual revenue with a 91.1% net margin and $75 million in free cash flow. From a quality standpoint, Rigel shows distressed Altman Z-Score of 0.6 warrants caution and extraordinary 186% return on equity. On valuation, the stock is deeply undervalued on a P/E basis at 1.6x, with offers a 69% margin of safety vs Graham Number of $97. Growth dynamics show revenue growing at 21.2% and profit growth of 1769.2%. Our composite FairStock Score of 95/100 reflects strong fundamentals overall. This combination of reasonable valuation, solid returns, and conservative leverage makes it worth a closer look for value-oriented portfolios.

Bull Case

Rigel's 21% revenue growth trajectory could accelerate as it captures additional market share in the healthcare sector. With $75 million in annual free cash flow (13.3% yield), management has ample capital for buybacks, dividends, or accretive acquisitions.

Bear Case

Macro headwinds or sector-specific disruption could pressure margins, particularly if competitive intensity increases in the healthcare space. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer